Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 4, 2010

Fumouze Diagnostics Inks Three-Year Distribution Deal with IVAX Diagnostics in France

  • Fumouze Diagnostics will be the exclusive third-party distributor of Diamedix and Delta Biologicals’ suite of diagnostic tests in France. The initial term of the agreement is three years.

    “As the international market for diagnostics increases in importance, one of our goals for 2010 is to increase our presence in key countries in Europe and South America,” remarks Charles Struby, Ph.D., CEO and president of IVAX Diagnostics, the parent company of Diamedix and Delta Biologicals.

    IVAX Diagnostics, headquartered in Miami, is an in vitro diagnostics company that develops, manufactures, and distributes reagents, test kits, and instrumentation through its two U.S. subsidiaries, Diamedix and ImmunoVision, as well as its Italian subsidiary, Delta Biologicals. Diamedix and Delta Biologicals have a combined suite of products that includes more than 200 diagnostics tests in the areas of infectious disease, autoimmune disease, and allergies. Delta Biologicals also manufactures a line of instruments for use in clinical and hospital laboratories.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »